neoadjuvant and adjuvant chemotherapy

PreclinicalSmall molecule

neoadjuvant and adjuvant chemotherapy is one of 57 small molecule programs targeting Breast Carcinoma. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Breast CarcinomaActive, not recruiting

Breast CarcinomaPreclinical

Active, not recruiting

Competition

Competitive Landscape

65 competitors in Breast Carcinoma

#DrugCompanyPhaseTrials

Ibrance

Pfizer

Approved

1 2

Afinitor

Novartis

Approved

1 3

Lynparza

Aliqopa

Mektovi

Piqray

Tykerb

Gemzar

Tagrisso

Trexall

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Recruiting

Breast Carcinoma

NCT04902937

Clinical

Trials by Indication[1]

Breast Carcinoma1 trial

Association of Adjuvant Radiotherapy of Non-metastatic Breast Carcinoma With Immunomodulation and Circulating Tumor Cell Phenotype in Relation to Patient Age.

Recruiting·UUniversity of Jena··NCT04902937·200 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for neoadjuvant and adjuvant chemotherapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — neoadjuvant and adjuvant chemotherapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for neoadjuvant and adjuvant chemotherapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Jena company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: UUniversity of Jena

neoadjuvant and adjuvant chemotherapy

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Breast Carcinoma1 trial

References

Drug Info

Quick Facts

Related News